Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Comparing the Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration

Chikako Hara
* ORCID logo ,
Masaki Suzue
,
Satoko Fujimoto
,
Yoko Fukushima
,
Kaori Sayanagi
,
Kentaro Nishida
,
Kazuichi Maruyama
,
Shigeru Sato
,
Kohji Nishida
Version 1 : Received: 9 November 2023 / Approved: 10 November 2023 / Online: 10 November 2023 (07:30:39 CET)

A peer-reviewed article of this Preprint also exists.

Hara, C.; Suzue, M.; Fujimoto, S.; Fukushima, Y.; Sayanagi, K.; Nishida, K.; Maruyama, K.; Sato, S.; Nishida, K. Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration. J. Clin. Med. 2024, 13, 385. Hara, C.; Suzue, M.; Fujimoto, S.; Fukushima, Y.; Sayanagi, K.; Nishida, K.; Maruyama, K.; Sato, S.; Nishida, K. Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration. J. Clin. Med. 2024, 13, 385.

Abstract

We compared the functional and morphologic effects in the loading dose between patients with treatment-naïve neovascular age-related macular degeneration treated with either intravitreal aflibercept (IVA) or intravitreal faricimab (IVF) injection in clinical settings. This retrospective study included 30 eyes from 28 patients who started IVA treatment between June and September 2022 and 30 eyes from 29 patients who started IVF treatment between October 2022 and March 2023. The mean best corrected visual acuity (BCVA) significantly improved from pre-treatment after loading dose in the IVA group (from 0.46 ± 0.46 to 0.36 ± 0.37, p=0.0047) and not in the IVF group (from 0.46 ± 0.41 to 0.44 ± 0.45, p=0.60). The mean central retinal thickness (CRT) significantly improved in both groups. The proportion of eyes with residual exudative change was greater in the IVF group than in the IVA group at 2 months after the first treatment. (p=0.026) We further analyzed the patients who obtained complete resolution of exudative changes after the loading dose. The IVA group had a significant improvement in BCVA, whereas the IVF group did not p=0.0047 and 0.20, respectively) Although IVA and IVF significantly improved the CRT, the BCVA improved significantly in IVA group and not in IVF group.

Keywords

age-related macular degeneration; aflibercept; faricimab; anti-vascular endothelial growth factor therapy; exudative change

Subject

Medicine and Pharmacology, Ophthalmology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.